Improvements of quality of life in patients with advanced non-small cell lung cancer treated with gefitinib

Chinese-German Journal of Clinical Oncology

Volumn 8, Issue 9, 2009, Pages 495-497

  Zou, Yanmei ^a   Xiong, Hua ^a   Yu, Shiying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gefitinib; Non small cell lung cancer (NSCLC); Quality of life (QoL)

Indexed keywords

GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; COGNITION; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DYSPNEA; EUROPIAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHYSICAL CAPACITY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS; SURVIVAL TIME; THORAX PAIN;

EID: 70349303625     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-009-0116-5     Document Type: Article

References (11)

1. Zhou QH, Wang J, Xu F. Clinical guideline of non-small cell lung cancer in 2005 national comprehensive cancer network. Chin J lung Cancer (Chinese), 2005, 8: 332-346.
2. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85: 365-376.
3. Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: A deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544.
4. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: A review of literature from 1970 to 1995. Chest, 1998, 113: 467-481.
5. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL1 Trial). J Clin Oncol, 2003, 21: 2237-2246.
7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 2003, 290: 2149-2158.
8. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30: 30-38.
9. Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol, 2003, 30: 39-48.
10. Guang ZZ, Zhang L, Li LY. Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: A clinical trial. Cancer (Chinese), 2005, 24: 980-984.
11. Zhang K, Zuo Q, Luo RC. Efficacy of Gefitinib in 36 patients with advanced non-small cell lung cancer. Chin Oncol (Chinese), 2006, 16: 878-879.